Frequently Asked Questions About Nizoral (Ketoconazole)
1.What is Nizoral (Ketoconazole)?
2.How Does Nizoral Work?
3.Which Fungal Infections Does Nizoral Address?
4.Can Nizoral Be Used for Nail Fungus?
5.How Long Until Nizoral Shows Results?
6.Is Nizoral Effective for Scalp Conditions?
7.In What Forms is Nizoral Available?
8.Can Nizoral Shampoo Be Used Daily?
9.Can Nizoral Be Used for Systemic Fungal Infections?
10.What Should I Do If I Miss a Dose of Nizoral Tablets?
11.Does Nizoral Have Side Effects?
12.Is Nizoral Safe for Children?
13.Can Nizoral Interact with Other Medications?
14.How Long Should I Use Nizoral Shampoo for Dandruff?
15.Can Nizoral Cause Allergic Reactions?
16.Is Nizoral Safe for Pregnant Women?
17.Is Alcohol Consumption Safe While Using Nizoral?
18.Can Nizoral Affect Birth Control Pills?
19.Can Nizoral Be Used for Fungal Infections in the Groin Area?
20.Is Nizoral Available Over-the-Counter?
21.Can Nizoral Shampoo Be Used for Hair Loss?
22.Can Nizoral Be Used for Yeast Infections?
23.Is Nizoral Shampoo Safe for Color-Treated Hair?
24.How Does Nizoral Cream Differ from Nizoral Shampoo?
25.Can Nizoral Tablets Cause Liver Damage?
26.Can Nizoral Be Used for Psoriasis?
27.Can Nizoral Shampoo Be Used on Dogs?
28.Can Nizoral Cause Photosensitivity?
📚 Sources Used for FAQ Content:
Information on ketoconazole (the active ingredient in Nizoral) is drawn from regulatory approvals across major markets, dermatology and infectious disease treatment guidelines, FDA safety communications including the 2013 black box warning for hepatotoxicity, and clinical experience accumulated since the medication's approval in 1981. Nizoral was developed by Janssen Pharmaceutica (Belgium, now part of Johnson & Johnson) as the first clinically used azole antifungal - a milestone that opened the era of broad-spectrum oral antifungal therapy.- U.S. FDA - Original 1981 approval; 2013 black box warning for hepatotoxicity restricted oral use
- European Medicines Agency (EMA) - 2013 EMA review withdrew oral ketoconazole marketing authorisation across EU
- UK MHRA - Following EMA decision, oral form withdrawn in UK 2013
- Belgian medicines agency - Country of origin regulator (Janssen Pharmaceutica)
- WHO Essential Medicines List - Topical ketoconazole listed for tinea versicolor and seborrheic dermatitis
- Health Canada, TGA Australia - Topical use approved; oral severely restricted
- Janssen / Johnson & Johnson - Original developer and historical brand holder
- American Academy of Dermatology guidelines - Topical ketoconazole for seborrheic dermatitis and tinea versicolor
- British Association of Dermatologists - UK clinical guidance for scalp conditions
- European dermatology guidelines - Standards for Malassezia-associated conditions
- National Eczema Association resources - Topical antifungals in seborrheic dermatitis management
- IDSA fungal disease guidelines - Why oral ketoconazole is no longer first-line
- Pediatric dermatology guidelines - Topical ketoconazole in children for selected indications
- 40+ years of clinical experience across topical and (formerly) oral use
- Cochrane systematic reviews - Seborrheic dermatitis, dandruff, tinea versicolor topical treatment
- Hepatotoxicity case series - Triggered the 2013 FDA black box warning
- FDA Drug Safety Communications - 2013 oral ketoconazole label changes
- EMA Article 31 review (2013) - Led to EU withdrawal of oral form
- UpToDate, DynaMed, BNF - Clinical decision support databases
- LiverTox (NIH) - Drug-induced liver injury resource - ketoconazole entry is extensive
Note: brand Nizoral and generic ketoconazole products are bioequivalent. The 2013 FDA black box warning applies to all oral ketoconazole; topical formulations are NOT affected by that warning.
FAQ Reviewed and Referenced By:
The Medication Guide content for Nizoral reflects published research and clinical guidance from internationally recognised authorities in dermatology, hair and scalp disorders, and medical mycology. The expert panel emphasises clinicians with deep experience in seborrheic dermatitis, Malassezia-associated conditions, and dermatologic mycology - the areas where ketoconazole has its strongest current role.
Cleveland Clinic - Cleveland, USA
Senior Staff Dermatologist and Director of Dermatopathology Fellowship at Cleveland Clinic. Past President of the American Academy of Dermatology. Internationally recognised authority on hair and scalp disorders, including seborrheic dermatitis and Malassezia-associated conditions where ketoconazole has its primary role.
University of Minnesota Medical School - Minneapolis, USA
Professor and Chair of Dermatology at the University of Minnesota. Past President of the North American Hair Research Society. Major authority on hair disorders, alopecia, and scalp dermatology - the clinical territory where Nizoral shampoo is most frequently prescribed.
Hospital General Dr. Manuel Gea González - Mexico City, Mexico
Director of the Mycology Section at one of Mexico's premier teaching hospitals. Internationally recognised medical mycologist specialising in superficial fungal infections including those caused by Malassezia. Author of "Micología Médica Ilustrada" - a standard Spanish-language mycology textbook.
University of Miami Miller School of Medicine - Miami, USA
Professor of Dermatology and Pediatrics. Past President of the Society for Pediatric Dermatology. Extensive expertise in pediatric dermatologic conditions including pediatric seborrheic dermatitis where topical Nizoral is commonly used at appropriate doses.
Andreas Sygros Hospital, University of Athens - Athens, Greece
Past President of the European Academy of Dermatology and Venereology (EADV). Internationally recognised clinician and researcher with broad dermatology expertise including Malassezia-associated conditions common in Mediterranean populations. Editor of multiple dermatology textbooks.
Note: this panel reflects published evidence and guidance from the listed authorities; it does not imply individual endorsement of this specific medication guide.
More Anti-Fungal Medications
